Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 10/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12366773 | 0.87 | HTR7 (0.41) | SLC9A1ADRA1DHTR2AHTR7HTR2B | |
| SCHEMBL12389307 | 0.86 | PLAU (0.46) | SLC9A1ADRA1DHTR2AHTR7HTR2B | |
| SCHEMBL12366828 | 0.86 | HTR7 (0.42) | SLC9A1ADRA1DHTR2AHTR7HTR2B | |
| SCHEMBL12390230 | 0.86 | SLC9A1 (0.43) | SLC9A1ADRA1DHTR2AHTR7HTR2B | |
| SCHEMBL12388304 | 0.86 | EPHX2 (0.42) | EPHX2 | |
| SCHEMBL12366899 | 0.85 | SLC9A1 (0.40) | SLC9A1ADRA1DHTR2AHTR7HTR2B | |
| SCHEMBL12389088 | 0.85 | EPHX2 (0.44) | EPHX2 | |
| SCHEMBL12390373 | 0.84 | HTR2B (0.49) | SLC9A1ADRA1DHTR2AHTR7HTR2B | |
| SCHEMBL12366747 | 0.83 | HTR7 (0.39) | SLC9A1ADRA1DHTR2AHTR7HTR2B | |
| SCHEMBL12390128 | 0.83 | HTR7 (0.42) | SLC9A1ADRA1DHTR2AHTR7HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2177505-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | SLC9A1 1693/4885ADRA1D 74/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.